Long-term Follow up Local Registry Study of Kymriah in South Korea
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci, którzy otrzymali lek Kymriah w ramach normalnego leczenia.
- •Pacjenci, którzy zgodzili się na zebranie swoich danych.
✗ Disqualifies
- •Pacjenci już objęci innym długoterminowym protokołem badania Kymriah (numer CCTL019A2205B).
Simplified criteria — AI translation
Trial details
- Minimum age
- 0 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
Novartis Investigative Site
Bundang Gu, South Korea
Novartis Investigative Site
Seongnam-si, South Korea
Novartis Investigative Site
Gyeonggi-do, South Korea
Novartis Investigative Site
Incheon, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Jeollanam, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Ulsan, South Korea
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.